NCLEX Review Guide: Guillain-Barré Syndrome

Disease Process

• Guillain-Barré Syndrome (GBS) is an acute inflammatory demyelinating polyneuropathy characterized by progressive, ascending muscle weakness and diminished or absent deep tendon reflexes. The immune system mistakenly attacks peripheral nerves, damaging the myelin sheath and sometimes the axons themselves, disrupting nerve signal transmission.
• GBS typically develops 1-3 weeks following a respiratory or gastrointestinal infection (most commonly Campylobacter jejuni, cytomegalovirus, Epstein-Barr virus, or Zika virus), suggesting an autoimmune response triggered by molecular mimicry between microbial antigens and peripheral nerve components.

Symptoms and Progression

• Initial symptoms include symmetric muscle weakness starting in the legs and progressing upward, accompanied by paresthesias (tingling/numbness) in the extremities. The weakness progresses over hours to days, potentially affecting respiratory muscles and causing respiratory failure in severe cases.
• Additional manifestations include areflexia (absent reflexes), autonomic dysfunction (blood pressure fluctuations, cardiac arrhythmias, urinary retention), facial weakness, difficulty swallowing, and pain (often described as severe, deep aching pain in weakened muscles).

Diagnostic Tests

• Lumbar puncture typically shows albuminocytologic dissociation (elevated protein with normal white blood cell count in cerebrospinal fluid). This finding may not be present early in the disease but develops in most patients within the first week.
• Electromyography (EMG) and nerve conduction studies (NCS) demonstrate slowed nerve conduction velocities, conduction block, or temporal dispersion consistent with demyelination. These electrophysiological studies help confirm the diagnosis and determine the subtype of GBS.
• Additional tests include complete blood count, metabolic panel, and tests to rule out differential diagnoses such as myasthenia gravis, botulism, or toxic neuropathies.

Immunotherapy

• Plasma exchange (plasmapheresis) removes antibodies and inflammatory mediators from the bloodstream. Treatment typically consists of 5 exchanges over 1-2 weeks and is most effective when initiated within the first 2 weeks of symptom onset.
• Intravenous immunoglobulin (IVIG) therapy neutralizes pathogenic antibodies and modulates the immune response. The standard regimen is 0.4 g/kg/day for 5 consecutive days, and it has similar efficacy to plasma exchange.

Supportive Care

• Respiratory support is critical, with continuous monitoring of vital capacity, negative inspiratory force, and oxygen saturation. Intubation and mechanical ventilation should be considered when vital capacity falls below 15-20 mL/kg or if there are signs of respiratory fatigue.
• Comprehensive care includes DVT prophylaxis, pressure injury prevention, pain management, nutritional support, psychological support, and early rehabilitation to prevent complications of immobility.

Respiratory Assessment Protocol

1. Measure vital capacity every 2-4 hours during the progressive phase
2. Monitor negative inspiratory force (NIF) and oxygen saturation
3. Assess for signs of respiratory distress: tachypnea, use of accessory muscles, paradoxical breathing
4. Consider intubation if vital capacity <20 mL/kg, NIF <30 cmH₂O, or worsening hypoxemia
5. Document and report any changes immediately

Priority Nursing Interventions

• Respiratory monitoring and management is the highest priority. Assess respiratory function frequently, position the patient to optimize ventilation, and be prepared for emergency intubation. Suction as needed and monitor for signs of respiratory infection.
• Monitor for autonomic dysfunction, including cardiac arrhythmias, blood pressure fluctuations, urinary retention, and ileus. Implement continuous cardiac monitoring and assess vital signs frequently.
• Provide comprehensive care to prevent complications of immobility: turn and reposition every 2 hours, perform passive range of motion exercises, implement pressure injury prevention measures, and ensure adequate nutrition and hydration.

Patient Education

• Educate patients about the typically self-limiting nature of GBS, with most patients recovering completely or with minimal residual deficits. However, recovery may take months to years, and patients need realistic expectations about the recovery process.
• Provide information about rehabilitation services, adaptive equipment, and community resources. Emphasize the importance of continuing physical and occupational therapy after discharge.

GBS vs. Multiple Sclerosis vs. Myasthenia Gravis

GBS Variants

• Miller Fisher syndrome is characterized by the triad of ophthalmoplegia (eye muscle weakness), ataxia, and areflexia. It accounts for about 5-10% of GBS cases and is associated with anti-GQ1b antibodies.
• Acute Motor Axonal Neuropathy (AMAN) affects only motor nerves with axonal damage rather than demyelination. It is more common in Asia and South America and often follows Campylobacter jejuni infection.

Priority Setting

• For NCLEX questions about GBS, remember that respiratory assessment and management are always the highest priority. Questions will often test your ability to recognize early signs of respiratory compromise that require immediate intervention.
• When prioritizing care for a GBS patient, follow Maslow's hierarchy with physiological needs first (breathing, cardiac function), then safety (preventing falls, pressure injuries), then psychosocial support.

Common NCLEX Question Themes

• Recognizing the clinical presentation of GBS, especially the ascending pattern of weakness and absent reflexes that differentiate it from other neurological conditions.
• Identifying appropriate nursing interventions for respiratory management, autonomic dysfunction, pain control, and prevention of immobility complications.
• Understanding the appropriate monitoring parameters for patients receiving immunotherapy (IVIG or plasmapheresis) and recognizing potential complications.

Critical Concepts

• Guillain-Barré Syndrome is an acute inflammatory demyelinating polyneuropathy characterized by progressive, ascending muscle weakness and diminished reflexes, typically following an infection.
• The hallmark clinical presentation includes symmetric ascending weakness, areflexia, paresthesias, and potential respiratory compromise and autonomic dysfunction.
• Diagnosis is based on clinical presentation, CSF analysis showing albuminocytologic dissociation, and electrophysiological studies.
• Treatment includes immunotherapy (IVIG or plasmapheresis) and comprehensive supportive care, with special attention to respiratory function.
• Nursing priorities include respiratory monitoring, preventing complications of immobility, managing autonomic dysfunction, pain control, and providing psychological support.